Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
70 hedge funds and large institutions have $14.2M invested in Unity Biotechnology in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 20 reducing their positions, and 13 closing their positions.
1,425% more call options, than puts
Call options by funds: $1.98M | Put options by funds: $130K
0.7% less ownership
Funds ownership: 2.53% → 1.83% (-0.7%)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
1% less funds holding
Funds holding: 71 → 70 (-1)
30% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 20
34% less capital invested
Capital invested by funds: $21.3M → $14.2M (-$7.19M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$1.77M |
| 2 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$252K |
| 3 |
Millennium Management
New York
|
+$225K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$125K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$82.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IFA
Invus Financial Advisors
New York
|
-$1.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.08M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$733K |
| 4 |
Two Sigma Investments
New York
|
-$429K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$240K |
UBX Hedge Fund Activity: Q1 2022 in Review
70 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q1 2022, worth a combined $14.2M — down 34% from $21.3M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of UBX and 12 opened new positions — a net loss of 1 holder — while 20 trimmed existing stakes and 14 added.
The largest buyer was Pura Vida Investments, opening a new position worth an estimated $1.77M. The largest seller was Invus Financial Advisors, exiting entirely with an estimated $1.6M sold.
- 70 institutional investors held Unity Biotechnology (UBX) as of Q1 2022, down from 71 in Q4 2021.
- Funds reported $14.2M of Unity Biotechnology stock for Q1 2022, down 34% quarter-over-quarter.
- 12 funds opened new Unity Biotechnology positions in Q1 2022 and 13 closed out, a net change of -1 holder.
- The largest Unity Biotechnology buyer in Q1 2022 was Pura Vida Investments, an estimated $1.77M added.
- The largest Unity Biotechnology seller in Q1 2022 was Invus Financial Advisors, an estimated $1.6M sold.
Based on aggregated 13F filings for Q1 2022.